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Introduction
Severe Gram-negative infections associated with shock still
carry a high mortality rate in spite of appropriate antibiotic
treatment and intensive care. Endotoxin, a component of the
outer cell wall of Gram-negative bacteria, is a powerful
inducer of the systemic inflammatory response that plays an
important role in the pathogenesis of septic shock [1]. Anti-
biotic treatment represents a key component of treatment for
R35
IL = interleukin; LBP = lipopolysacharide-binding protein; MAP = mean arterial pressure; MPAP = mean pulmonary artery pressure; TNF = tumour
necrosis factor.
Abstract
Introduction Antibiotics used for treatment of severe bacterial infections have been shown to exert
effects on the inflammatory response in addition to their antibacterial effects. The aim of the present
study was to investigate whether the biological effects of endotoxin in a porcine model could be
neutralized by tobramycin, and whether tobramycin or ceftazidime was able to modulate the
inflammatory response.
Method Thirteen piglets were subjected to endotoxin infusion at an initial rate of 4µg/kg per hour,
which was reduced to 1µg/kg per hour after 30 min. Before endotoxin infusion, the animals received
saline (n=4), ceftazidime (n=5), or tobramycin (n=4) at clinically relevant doses. Physiological
parameters were measured and blood samples were taken hourly for 6 hours for analysis of tumour
necrosis factor-α, IL-6 and endotoxin concentrations.
Results All of the animals exhibited physiological signs of severe sepsis without major differences
between the groups. Plasma endotoxin concentration was stable after 1 hour. There were no
differences in endotoxin concentration or initial tumour necrosis factor-α and IL-6 concentrations
between the groups. At 6 hours the IL-6 concentration was significantly lower in the ceftazidime group
than in the saline group (P<0.05), and in both the ceftazidime and the tobramycin groups there were
significantly greater reductions from peak values (P<0.05).
Conclusion There was no neutralization of the biological effects of endotoxin in this porcine model.
However, our data indicate a possible anti-inflammatory effect exerted by both ceftazidime and
tobramycin, which manifested as a significantly greater reduction in IL-6 in comparison with the
untreated group.
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severe bacterial infection [2], but in addition to their antibac-
terial effect several antibiotics have been shown to exert
effects on the inflammatory response. In numerous studies,
both in vitro and in vivo, endotoxin in various amounts was
released when Gram-negative bacteria were exposed to
certain antibiotics, such as β-lactam antibiotics, which are
commonly used for the treatment of severe sepsis [1–3]. On
the other hand, aminoglycosides have been associated with
low release of endotoxin [4,5].
The mechanism underlying this effect of aminoglycosides is
not clear but nonspecific binding and neutralization of endo-
toxin, similar to polymyxin B, have been proposed as the prin-
cipal modes of action by some investigators [3,4,6]. In
contrast to this, results from a recent study [7] showed that
tobramycin did not neutralize endotoxin in vitro and that the
effect was more probably due to a de facto low release of
endotoxin. The absence of in vitro neutralization indicates that
no aminoglycoside binding occurs that affects biological
activity in the limulus amoebocyte lysate assay, but on the
other hand a tobramycin binding that neutralizes the endo-
toxin effect in vivo cannot be excluded. Inhibition of the
binding of endotoxin to lipopolysaccharide-binding protein
(LBP), which is the most important carrier protein in the body
and is crucial for attachment to the CD14 receptor on the
macrophages, represents one possible mode of action.
Another possibility is that binding with LBP is unaffected
whereas the tobramycin–endotoxin–LBP complex has
reduced affinity for the CD14 receptor or lower potential to
elicit a signal via Toll-like receptor 4.
The aim of the present study was to investigate whether the
biological effects of endotoxin in a porcine in vivo model can
be neutralized by addition of tobramycin. The primary end-
points were the tumour necrosis factor (TNF)-α and IL-6
responses after 1 and 2 hours, respectively, in relation to
endotoxin concentrations. These time points were chosen
because cytokine values obtained later might be influenced
by an aminoglycoside-induced protection against oxidative
injury, which has been demonstrated in vitro [8].
Oxidative stress, which occurs mainly after maximal activa-
tion of neutrophils and establishment of shock [9], has been
shown to induce a proinflammatory cytokine response
[10,11]. In several in vitro experiments similar oxygen
radical protective effects have been shown for some of the
β-lactam antibiotics [12], of which ceftazidime appears to
be the most investigated [13]. If this effect occurred in vivo,
then it would influence the cytokine values during the last
part of the experiment. Therefore, a secondary aim of the
study was to investigate whether tobramycin and the
β-lactam antibiotic ceftazidime could reduce cytokine con-
centrations at the end of the observation period. An addi-
tional secondary aim was to study the effect of tobramycin




The study included 13 domestic breed piglets of both sexes
from different litters, weighing between 20 and 26kg (median
24kg). The animals were 12–14 weeks old and were without
evidence of illness. Animals included in the study had an arter-
ial oxygen tension greater than 10kPa (75mmHg) and a mean
pulmonary artery pressure (MPAP) below 2.7kPa (20mmHg)
at baseline, 20 min after completion of the preparatory proce-
dure (see below). The Ethics Committee of Uppsala University,
Sweden, approved the experiment. The piglets were treated
according to the European Convention on Animal Care.
Anaesthesia
Anaesthesia was induced with 6mg/kg tilétamin-zolazepam
(Zoletil forte vet™, Boehringer Ingelheim Vetmedica, Ingel-
heim, Germany), mixed with 2.2mg/kg of xylazin (Rompun
Vet™, Bayer, Leverkusen, Germany) and atropine 0.04mg/kg
(Atropin™, NM Pharma, Stockholm, Sweden). Anaesthesia
was maintained by continuous infusion of sodium pentobarbi-
tal 8mg/kg per hour (Pentobarbitalnatrium™, Apoteket, Umeå,
Sweden), pancuronium bromide 0.26mg/kg per hour
(Pavulon™, Organon, Oss, The Netherlands) and morphine
0.48mg/kg per hour (Pharmacia, Uppsala, Sweden) dis-
solved in a 2.5% glucose–electrolyte solution. During the
experiment, sodium chloride infusion was given, resulting in a
total fluid administration rate of 30ml/kg per hour.
Preparatory procedure
A bolus dose of 20mg morphine was given intravenously
before performance of a tracheotomy, which was done in
order to secure a free airway during the experiment and to
administer nitrous oxide during surgical preparation. The
animals were artificially ventilated throughout the experimental
procedure (Servo 900C™, Siemens Elema, Stockholm,
Sweden). During catheter insertions 30% oxygen in nitrous
oxide was given. The gas mixture was switched to 30%
oxygen in air during the rest of the experiment. The ventilation
after preparation was set to yield an arterial carbon dioxide
tension between 5.0 and 5.5kPa. The respiratory rate was
25 breaths/min and the inspiratory–expiratory ratio was 1:3.
Ventilator settings were then kept constant throughout the
experiment. Atelectasis was prevented by placing the piglets
into the prone position after preparatory procedures and by
maintaining a positive end-expiratory pressure of 5cmH2O
[14]. A central venous line and a 7Fr Swan–Ganz catheter
equipped with thermistor were inserted through the internal
jugular vein into the superior caval vein and the pulmonary
artery, respectively. In addition, a cervical artery was catheter-
ized with an arterial line used for blood sampling and continu-
ous measurement of arterial blood pressure. A minor
vesicotomy was performed for placement of the urinary
catheter and a heating pad (Operatherm 200W™, KanMed,
Bromma, Sweden) was used to keep the animals at a con-
stant body temperature.R37
Administration of endotoxin and antibiotics
Once the preparatory procedure was completed, at least
20 min stabilization time was allowed to pass before base-
line values were registered and baseline blood samples were
taken before administration of antibiotics and endotoxin. All
animals were subjected to endotoxin infusion (Escherichia
coli O111:B4; Sigma Chemical, St. Louis, MO, USA) with
an initial infusion rate of 4µg/kg per hour. After 30 min the
infusion rate was reduced to 1µg/kg per hour, which was
continued during the rest of the experiment. At least a
twofold increase in MPAP (mmHg) was taken as a sign of
severe endotoxaemic shock. This regimen was described
previously [15,16].
If the mean arterial pressure (MAP; mmHg) decreased to the
level of the MPAP during the first hour of the experiment,
then a single dose of 0.2mg adrenaline was given intra-
venously. Values were registered hourly after baseline for
6 hours, after which all surviving piglets were killed by an
intravenous overdose of potassium chloride.
The animals were randomized using the sealed envelope
method to receive tobramycin, ceftazidime, or saline solution.
Tobramycin was given as an intravenous infusion of 140mg
in 100ml saline solution for 20 min, starting 10 min before ini-
tiation of endotoxin infusion. Ceftazidime was injected as an
intravenous bolus dose of 1g in 10ml saline 5 min before the
start of endotoxin infusion, followed by 90ml saline for a total
infusion time of 10 min. In the control group an infusion of
100ml saline was initiated 5 min before the start of endotoxin
administration and was given for 10 min.
Antibiotics
The antibiotics were obtained as reference substances with
known potencies. Ceftazidime was purchased from Glaxo
Wellcome AB (Gothenburg, Sweden) and tobramycin from
Eli Lilly Sweden AB (Stockholm, Sweden). The doses were
calculated to achieve similar concentrations to those with
commonly recommended maximal doses for treatment of
clinical sepsis.
Measurements
MAP and MPAP were continuously monitored through the
arterial and the Swan–Ganz catheters, respectively. The
central line was used for injection of 10ml cold saline for
determining cardiac output (l/min). Cardiac output was
expressed as cardiac index, and body surface area was cal-
culated as weight0.67 ×0.112. Cardiac index was assessed
hourly by the thermodilution method using the thermistor in
the Swan–Ganz catheter. The average value from at least
three serial measurements was registered. Heart rate was
continuously monitored. Blood samples for analysis of endo-
toxin, TNF-α and IL-6 were drawn immediately before addition
of antibiotics and hourly until the end of the experiment. At
the same time points arterial blood gas and base deficit were
analyzed (ABL™ 300, Radiometer, Brønhøj, Denmark).
Determination of endotoxin, tumour necrosis factor-α α
and interleukin-6
Endotoxin-free heparinized tubes (Endo Tube; Chromogenix
AB, Mölndal, Sweden) were used for the endotoxin samples.
Samples for TNF-α and IL-6 were drawn in EDTA tubes. After
centrifugation the supernatants were transferred to endotoxin-
free tubes and subsequently kept at –70°C until analysis.
Analysis of endotoxin was performed in duplicate with the
limulus amoebocyte lysate assay (Coatest™ Plasma Chromo-
LAL; Charles River Endosafe, Charleston, SC, USA) [17].
Commercial sandwich enzyme-linked immunosorbent assays
were used for detection of IL-6 (Quantikine™ porcine IL-6,
P6000; R&D Systems, Minneapolis, MN, USA) and TNF-α
(KSC3012; Biosource International, Nivelles, Belgium).
Number of animals and statistical analysis
The TNF-α response at 1 hour and the IL-6 response at
2 hours were compared in the primary analyses of the immedi-
ate initial cytokine response. Because there was a variation in
the immediate cytokine response, the reduction in concentra-
tions of TNF-α and IL-6 from 1 hour and 2 hours, respectively,
to 6 hours, as well as the concentrations at 6 hours, were con-
sidered late cytokine responses. In order to detect a differ-
ence in the initial log concentration of cytokines of at least
20% with an α error of 0.05, a β error of 0.2, a power of 0.8,
and a calculated interindividual variation of 14%, eight evalu-
able animals were needed in each treatment group. In this
exploratory trial an interim analysis was planned when there
were at least four animals in each group that had survived for
6 hours. The distribution of the logarithm of initial cytokine
response approximates the Normal distribution in this model,
and was therefore analysed using an unpaired t-test.
Other differences between treatment groups were calculated
using the nonparametric Mann–Whitney U-test. The results
are expressed as mean±standard error or as median±range.
P<0.05 was considered statistically significant.
Results
There were no significant differences in physiological base-
line variables between the groups (Table 1). These values
were all within the normal ranges [18]. One pig in the cef-
tazidime group died 4 hours after the start of the experiment.
At the interim analysis, it was concluded that intersubject vari-
ation was not greater than expected and that addition of
further animals would not change the final result. Thus, the
study was terminated when 13 pigs had been included.
Tumour necrosis factor-α α and interleukin-6 levels
Plasma TNF-α and IL-6 concentration values are shown in
Tables 2 and 3. The plasma TNF-α levels reached peak
values 1 hour after the start of endotoxin infusion, with a
median value of 7265ng/l (range 2492–10625ng/l). There
were no significant differences in peak TNF-α values between
the treatment groups. TNF-α concentration decreased to
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baseline levels within 3 hours in most animals (Fig.1). There
were no differences in the elimination rates between treat-
ment groups or TNF-α concentration at 6 hours.
Plasma IL-6 levels peaked after 2 or 3 hours, with a median
maximum IL-6 value of 2372ng/l (range 1544–7138ng/l).
There were no significant differences in IL-6 concentration at
2 hours between treatment groups. At 6 hours the IL-6 con-
centration was significantly lower in the ceftazidime group
than in the saline group (P<0.05). Furthermore, the reduc-
tion in IL-6 seen both in the animals treated with ceftazdime
and in those treated with tobramycin was significantly greater
than that in the animals receiving saline (P<0.05; Fig.2).
Plasma endotoxin levels
Plasma endotoxin concentrations are shown in Fig.3. The
initial plasma samples obtained before the start of endotoxin
infusion were taken after the preparatory procedure (i.e. vesi-
cotomy and insertion of a central venous catheter through the
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Table 1
Physiological parameters during endotoxin infusion
Parameter
Group
Time (h) Saline Ceftazidime Tobramycin
Mean pulmonary arterial pressure (mmHg)
0 16.5 ± 0.9 17.4 ± 0.9 18.0 ± 2.4
1 29.0 ± 2.7 29.4 ± 1.5 30.5 ± 3.3
2 34.8 ± 3.1 35.2 ± 2.4 37.5 ± 2.6
3 36.3 ± 3.6 39.8 ± 3.3 37.0 ± 2.9
4 32.5 ± 1.3 36.0 ± 3.2 32.5 ± 1.6
5 30.8 ± 0.6 36.0 ± 4.0 30.0 ± 2.1
6 29.3 ± 0.9 35.5 ± 3.8 28.3 ± 2.7
Mean arterial pressure (mmHg)
0 87.5 ± 11.6 104.2 ± 5.6 100.5 ± 13.9
1 119.0 ± 6.4 120.4 ± 8.9 87.8 ± 8.8
2 113.3 ± 6.2 110.2 ± 10.5 101.3 ± 5.7
3 93.0 ± 8.1 98.0 ± 14.8 97.3 ± 6.3
4 92.0 ± 19.1 94.0 ± 18.4 101.3 ± 8.5
5 95.0 ± 22.1 115.8 ± 8.6 107.5 ± 7.8
6 104.3 ± 21.9 120.0 ± 10.0 108.5 ± 7.1
Cardiac index (l/min per m2)
0 4.6 ± 0.2 4.2 ± 0.1 4.0 ± 0.3
1 4.4 ± 0.4 4.2 ± 0.5 3.5 ± 0.2
2 3.6 ± 0.3 3.0 ± 0.3 2.6 ± 0.2
3 2.3 ± 0.2 2.1 ± 0.3 1.9 ± 0.1
4 2.5 ± 0.4 2.2 ± 0.4 2.0 ± 0.1
5 3.2 ± 0.6 3.2 ± 0.4 2.8 ± 0.3
6 3.8 ± 0.7 3.7 ± 0.4 3.4 ± 0.5
Arterial oxygen tension (kPa)
0 21.1 ± 0.5 22.3 ± 0.4 21.1 ± 1.2
1 20.1 ± 0.7 21.0 ± 1.6 17.8 ± 2.9
2 19.1 ± 0.7 18.7 ± 1.8 16.5 ± 3.2
3 17.3 ± 1.1 17.7 ± 2.1 14.8 ± 3.0
4 17.7 ± 0.5 17.1 ± 1.8 15.2 ± 2.5
5 18.0 ± 0.6 17.9 ± 1.5 17.1 ± 2.4
6 18.0 ± 0.5 17.8 ± 1.7 17.3 ± 2.4
Base excess (mmol/l)
0 7.0 ± 1.1 5.6 ± 0.7 6.5 ± 0.5
1 3.0 ± 0.9 1.2 ± 1.0 1.0 ± 0.8
2 2.3 ± 0.9 1.4 ± 1.0 1.3 ± 0.5
3 –0.8 ± 1.1 –1.8 ± 2.3 –1.0 ± 0.7
4 –2.8 ± 2.2 –5.0 ± 3.6 –1.8 ± 0.5
5 –1.0 ± 2.3 –0.3 ± 0.8 –0.8 ± 0.3
6 0.0 ± 1.7 –0.5 ± 0.8 –0.8 ± 0.3
Neutrophil granulocyte count (109/l)
0 6.9 ± 2.0 6.3 ± 1.5 5.7 ± 1.5
1 1.4 ± 0.2 1.0 ± 0.2 0.9 ± 0.2
2 0.9 ± 0.2 1.5 ± 0.6 0.4 ± 0.2
3 1.8 ± 0.4 2.4 ± 0.6 1.5 ± 0.6
4 2.3 ± 0.4 2.4 ± 0.7 1.8 ± 0.4
5 3.4 ± 0.3 2.8 ± 0.3 3.1 ± 1.1
6 4.0 ± 0.2 2.9 ± 0.7 5.1 ± 1.9
Values are expressed as mean ± standard error.
Figure 1
Plasma tumour necrosis factor (TNF)-α concentrations 1–6 hours after
start of endotoxin infusion (n=4). SE, standard error.
Figure 2
Plasma IL-6 concentrations 2–6 hours after start of endotoxin infusion
(n=4).R39
skin), and therefore endotoxin contamination cannot be
excluded. Despite this, plasma endotoxin was low
(1.61±0.47endotoxin units/ml) in eight of the animals.
However, in five animals – three in the tobramycin group and
one from each of the other two groups – there were consider-
ably higher levels (15.5±2.9EU/ml). In these animals there
were no concomitant increases in TNF-α or IL-6 concentra-
tions or signs of infection, and all of them responded physio-
logically to the endotoxin infusion with a doubling of the
MPAP. In three animals – two in the tobramycin group and
one in the saline group – there was even a decrease in endo-
toxin concentration after 1 hour of endotoxin infusion. Conse-
quently, because contamination cannot be excluded in any of
the samples, plasma concentration before the start of infusion
was set to zero.
As shown in Fig.3, neither tobramycin nor ceftazidime had an
endotoxin neutralizing effect in comparison with that con-
ferred by saline. The endotoxin levels remained stable after
1 hour into the experiment.
Physiological variables
Physiologic variables are shown in Table 1. All pigs given
endotoxin responded to this challenge with a marked rise in
MPAP, and elevated levels persisted throughout the experi-
ment. Cardiac index and arterial oxygen tension decreased,
whereas base deficit increased and MAP showed minor vari-
ations in all three groups during endotoxin infusion.
The neutrophil granulocyte counts showed a fourfold to
sixfold decrease after the first hour, which was followed by a
gradual increase (Table 1). At 6 hours the neutrophils were
still substantially lower than baseline counts.
There were no significant differences in circulatory, respira-
tory, or haematological variables between the groups.
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Table 2
Plasma tumour necrosis factor-α α levels during endotoxin infusion
Group
Saline Ceftazidime Tobramycin
Time (h) n Plasma TNF-α n Plasma TNF-α n Plasma TNF-α
0 4 < 15 (< 15–16) 5 < 15 (0) 4 < 15 (< 15–49)
1 4 7259 (6584–10375) 5 7265 (5071–10625) 4 6789 (2492–8728)
2 4 2473 (803–3964) 5 1683 (1142–2134) 4 1397 (697–2009)
3 4 37 (26–137) 5 58 (39–68) 4 61 (22–156)
4 4 16 (< 15–33) 5 < 15 (0) 4 19 (< 15–53)
5 4 < 15 (0) 4 < 15 (0) 4 < 15 (< 15–49)
6 4 < 15 (0) 4 < 15 (0) 4 < 15 (< 15–33)
Values are expressed as ng/l (median [range]). TNF, tumour necrosis factor.
Table 3
Plasma IL-6 levels during endotoxin infusion
Group
Saline Ceftazidime Tobramycin
Time (h) n Plasma IL-6 n Plasma IL-6 n Plasma IL-6
0 4 < 10 (0) 5 < 10 (0) 4 < 10 (0)
1 4 261 (35–931) 5 223 (83–1145) 4 761 (315–2362)
2 4 1492 (1192–2536) 5 1793 (1024–5124) 4 4519 (1894–7004)
3 4 2305 (1695–2464) 5 1865 (1544–7138) 4 4168 (1658–5171)
4 4 1523 (810–2509) 5 1143 (738–7854) 4 1685 (1236–1854)
5 4 839 (192–2336) 4 468 (292–563) 4 778 (493–1070)
6 4 426 (313–1797) 4 204 (128–239) 4 370 (264–623)
Values are expressed as ng/l (median [range]).R40
Discussion
In the present porcine endotoxin model, the dose of endo-
toxin given was high enough to result in a hypodynamic septic
shock. Recently, low-dose endotoxin animal models have
been described that result in a hyperdynamic circulation that
mimics more closely the circulatory changes that occur in
human clinical sepsis [19]. However, because the aim was to
study neutralization of endotoxin and endotoxin-induced bio-
logical effects, a high-dose model was chosen in order to
allow a relatively short observation time and to avoid low pre-
cision of measurements as a result of endotoxin levels that
were too low. The initial TNF-α and IL-6 concentrations were
chosen as primary end-points because endotoxin has been
shown to induce a quick and reproducible response both in
vitro and in animal models [20], and at 1 and 2 hours it is
unlikely that any downstream effects will affect the result to
any great extent. However, it must be pointed out that there
may be a risk that this model will fail to exclude a possible
antiendotoxin effect if endotoxin–aminoglycoside binding is
subject to saturation kinetics and if a lower endotoxin dose is
used. In order to minimise such a risk, the tobramycin dose
chosen was at the upper end of the range used clinically.
With four animals in each group the detectable difference is
25%, given the same power and α error. As shown in Tables
1 and 2, and in Figs 1 and 2, there was no tendency toward a
reduction in the immediate cytokine response. This indicates
that there is no in vivo neutralization of endotoxin-induced
cytokine production, and consequently that there is no inter-
action with binding to LBP or the CD14 receptor. Further-
more, there was no neutralization of the circulating endotoxin,
which is in agreement with in vitro results [7]. In fact, there
was a tendency for the endotoxin concentration in animals
treated with tobramycin to be higher, which might be consis-
tent with reduced binding to the CD14 receptor. However,
the corresponding increase in IL-6 concentration and the
unchanged TNF-α values strongly indicate that this was not
the case. Although there is a need to confirm this result in a
low-dose endotoxin model, our results indicate that there is
no neutralization of endotoxin by tobramycin. As a conse-
quence, the advantage of using an aminoglycoside for treat-
ment of severe sepsis and septic shock may mainly be due to
its broad antibacterial spectrum, to its rapid bactericidal
effect, and possibly also to low endotoxin release per killed
bacterium and inhibition of penicillin binding protein-3
induced endotoxin release [5].
The inflammatory damage to endothelial cells and other tissue
cells mediated by oxygen radicals induces cytokine produc-
tion [9,21]. In several in vitro experiments it has been demon-
strated that ceftazidime and some of the other β-lactam
antibiotics inactivate hypochlorous acid [22] and, in the case
of ceftazidime, singlet oxygen [23]. In clinically relevant con-
centrations, ceftazidime has also been shown to protect
endothelial cells partly from the oxidative stress of activated
neutrophils in vitro [9]. The documentation for aminoglyco-
sides is less extensive but both tobramycin and gentamicin
have been shown to protect lung epithelial cells against
myeloperoxidase-dependant oxidant injury by binding to
anionic cell surfaces and neutralizing hypochlorous acid [8].
These findings led to the hypothesis that the anti-inflamma-
tory effects might affect the cytokine response during the last
phase in our porcine model. At the end of the experiment,
there was a treatment effect that was manifested as a signifi-
cantly greater reduction in IL-6 by ceftazidime and
tobramycin, and a lower absolute IL-6 level in the ceftazidime
group, as compared with the placebo group. Because there
are  in vitro data indicating that ceftazidime directly affects
neither IL-6 production [24] nor neutrophil function [25], this
result might have been caused by its antioxidative properties.
For tobramycin, in vitro data indicate that neutrophil function
and oxidative metabolism might be influenced, but these
results have not been reproduced in vivo [24]. Whether our
findings are due to antioxidative properties of the antibiotics
or to other mechanisms cannot be concluded from the data
presented, but the findings indicate that anti-inflammatory
properties reported in vitro may be demonstrable in animal
models also. With our short observation time, it was not pos-
sible to see whether this reduction was continued or whether
it would have any impact on haemodynamic parameters.
Conclusion
The biological effects of a 6 hour continuous infusion of endo-
toxin were not neutralized by tobramycin in this porcine
model. However, data indicate a possible anti-inflammatory
effect from both ceftazidime and tobramycin. The mecha-
nisms, physiological consequences and potential clinical rele-
vance of this finding need further investigation.
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Figure 3
Plasma endotoxin concentration during endotoxin infusion (4µg/kg per
hour during 30 min followed by 1µg/kg per hour until the end of
experiment). Time 0=start of endotoxin infusion. The values obtained
at time 0 have been set to zero. In the saline and the tobramycin
groups n=4. In the ceftazidime group n=5 at 1, 2, 3 and 4hours;
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Key messages
• The biological effects of endotoxin were not neutralized
by ceftazidime or tobramycin
• There was a significantly greater reduction in IL-6 in
pigs treated with ceftazidime and tobramycin as com-
pared with those given saline, indicating a possible
anti-inflammatory effect of both antibiotics